Baylor Charles A. Sammons Cancer Center at Dallas

Dallas, Texas 75246

0 studies enrolling now · 5 studies all time

What they study most

Colorectal Cancer, Multiple Myeloma, Plasma Cell Leukemia, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Solid Tumors

Studies at this site

• Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet — Completed
• Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. — Completed
• A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors — Completed
• Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable) — Completed
• A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma — Completed